GovWire

Decision: Early access to medicines scheme: expired scientific opinions

Medicines Healthcare Products Regulatory Agency

March 31
13:59 2023

Details

These products were granted a positive scientific opinion (SO) by the Medicines and Healthcare products Regulatory Agency (MHRA) under the early access to medicines scheme (EAMS). The positive opinion for these products has expired following either the approval of marketing authorisation or withdrawal from the scheme.

Published 27 July 2015
Last updated 31 March 2023 +show all updates
  1. 'Efgartigimod alfa in the treatment of myasthenia gravis (gMG)' added to Expired early access to medicines scheme scientific opinions list.

  2. Added Ascimib to the expired list

  3. Voxelotor Public Assessment Report (PAR) withdrawn. Added to Expired list

  4. Added 'Avalglucosidase alfa in the treatment of late-onset Pompe disease' to the expired list.

  5. Abrocitinib in the treatment of severe atopic dermatitis, added to expired SO page

  6. Addition of nivolumab in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the first-line treatment of adult patients with HER2 negative (or undetermined) advanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma.

  7. Added new entry - 'Tepotinib in the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition factor gene (MET) exon 14 (METex14) skipping alterations'

  8. Updated the list of expired EAMS SO

  9. Granting of marketing authorisation for Lumasiran in the treatment of primary hyperoxaluria type 1 (PH1) in all age groups

  10. Added 'Avelumab in the treatment of bladder cancer' to the list of expired opinions.

  11. Added 'Nivolumab' to the Expired scientific opinions list

  12. Addition of expired early access to medicine scientific opinion due to granting of marketing authorisation for Atezolizumab in combination with bevacizumab for the treatment of adult patients with unresectable hepatocellular carcinoma who have received no prior systemic therapy

  13. Addition of Raxone due to discontinuation of EAMS programme at the request of the company

  14. Added remdesivir to the list of expired scientific opinions

  15. Added Isatuximab (for relapsed and refractory multiple myeloma) to list of expired scientific opinions.

  16. Added new entry (Tafamidis) to HTML attachment

  17. Updating due to granting of the EU licence for Polatuzumab vedotin (for non-Hodgkin Lymphoma)

  18. We have updated the Early access to medicines scheme: expired scientific opinions

Related Articles

Comments

  1. We don't have any comments for this article yet. Why not join in and start a discussion.

Write a Comment

Your name:
Your email:
Comments:

Post my comment

Recent Comments

Follow Us on Twitter

Share This


Enjoyed this? Why not share it with others if you've found it useful by using one of the tools below: